Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INHIBITOR: HBV NAT+ Donors for Vaccinated Lung Transplant Candidates
NCT05404919Phase 2Withdrawn
- Sponsor
- University of Pennsylvania
- Start
- Sep 2022
- Primary completion
- Aug 2024
- Modality
- Antibody Conjugates, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of hepatitis B immune globulin, entecavir, tenofovir disoproxil fumarate, tenofovir alafenamide in hepatitis B (HBV), sponsored by University of Pennsylvania. Planned start Sep 2022; status: withdrawn.
02
Drugs
hepatitis B immune globulinentecavirtenofovir disoproxil fumaratetenofovir alafenamide
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05404919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05404919.